NCT02044328View on ClinicalTrials.gov

Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

January 31, 2018

Study Completion Date

October 31, 2021

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Icotinib

Icotinib is administered 125 mg three times per day.

Trial Locations (1)

100053

Xuanwu Hospital, Capital Medical University, Beijing

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY